Skip to main content

Table 1 Clinical and metabolic patient variables (all of the patients and grouped according to macro-vascular involvement)

From: Macrovascular complication phenotypes in type 2 diabetic patients

Variables All NMVD (I) NSCS (II) CBVD (III) CAD (IV) PAD (V) PVD (VI) p differencesamong the groupsa
N patients (%) 1199 643 (53.6) 69 (5.7) 81 (6.8) 89 (7.4) 59 (4.9) 258 (21.5) _
Age (yy) 67 (58–75) 63 (55–72) 66 (59–71) 73 (66–79) 65 (55–75) 72 (65–76) 73 (67–78) I≠III,V,VI***, II≠III**,VI*** III≠IV***, IV≠V*,VI***
Sex %M 49.5 45.3 39.1 37 58.4 61 61.2 ***
DM2 duration (yy) 12 (6–20) 10 (5–18) 10 (5–15.5) 12.5 (7–20) 14 (6–20) 20 (10–30) 20 (10–28.3) I≠V,VI***, II≠V,VI***, III≠VI*, IV≠VI**
Weight (Kg) 80 (69.5-92.7) 81 (71.1-94.4) 80.1 (67.3-93.8) 74.6 (65.1-85.5) 85.7 (74.4-98.6) 75.2 (67–90) 76.5 (65.4-87.8) I≠III,VI**, III≠IV***, IV≠VI**
BMI (Kg/m2) 31.1 (27.6-35.5) 31.5 (28.1-36.4) 31.5 (26.5-36.6) 29.7 (27.1-33.6) 32.2 (27.6-37) 30.3 (26.3-34.9) 30 (26.3-33.8) I≠VI**, IV≠VI*
WC (cm) 105 (97–118) 106 (97–120) 105.5 (94.3-119) 102 (96–110.5) 110 (98–120) 103 (98–115.8) 104 (97–116) ns
Smoking history % 27.3 26.9 20.3 14.8 25.8 33.9 32.6 ***
SBP (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–145) 130 (120–140) ns
DBP (mmHg) 80 (70–80) 80 (70–80) 80 (70–80) 70 (70–80) 80 (70–80) 70 (70–80) 80 (70–80) ns
TC (mg/dl) 178 (151–210) 183 (157–212) 201 (175–221) 176 (153–204) 162 (132–193) 179 (156–212) 165 (135–196) I≠IV,VI***, II≠IV,VI***
HDL-C (mg/dl) 45 (38–55) 47 (39–57) 49 (39–58) 47 (41–60) 42 (35–50) 45 (39–55) 43 (35–52) I≠IV*,I≠VI***, III≠IV,VI*
LDL-C (mg/dl) 102(77–131) 105(83–133) 121(99–144) 101(76–129) 82 (64–116) 102(74–130) 91 (70–123) I≠IV,VI***, II≠IV,VI***
TG (mg/dl) 124 (91–166) 123 (91–161) 125 (96–173) 117 (82–149) 126 (94–184) 123 (90–170) 130 (91–176) ns
HbA1c (%) 8.1 (7–9.5) 8.1 (7.1-9.7) 8 (6.9-10.2) 8.2 (6.8-9.5) 8.1 (7.2-9.5) 7.7 (6.8-9) 8 (7–9.3) ns
FPG (mg/dl) 174 (139–224) 174 (138–230) 177 (148–232) 169 (138–213) 182 (142–222) 177 (140–218) 174 (137–219) ns
2h-BG (mg/dl) 201 (160–265) 203 (160–270) 219 (174–286) 195 (160–232) 205 (160–270) 200 (167–239) 200 (155–254) ns
∆BG (prandial) 34 (−6-76) 35 (−3-79) 44 (14–81) 39 (−8-88) 38 (−1-61) 31 (−22-58) 22 (−16-69) ns
MetS % 88 83.1 91.3 88.9 89 94.9 95.7 ***
3-4 MetS factors % 61 55.7 62.3 64.2 73 69.5 66.7 ***
eGFR 84 (65–101) 89 (74–106) 87 (61–100) 79 (65–99) 82 (57–103) 66 (49–88) 68 (50–88) I≠III*,V,VI***, II≠V*, II≠VI**, IV≠VI*
Albuminuria % 25.9 24.3 21.9 25.3 31.8 33.3 27.2 ns
DR % 37.3 28.6 33.3 40.7 38.2 78 49.2 ***
DN % 49.7 39.0 42.0 53.1 43.8 88.1 70.5 ***
Statin users % 65 55.4 69.6 70.4 76.4 81.4 78.7 ***
AH user % 80.4 72.3 79.7 85.2 91 96.6 91.9 ***
OHA users % 38.3 43.2 49.3 42 39.3 20.3 25.6 ***
OHA+BI users % 13.6 16.5 11.6 8.6 10.1 10.1 10.5 ***
MDI users % 48.1 48.1 39.1 49.4 50.6 69.3 63.9 ***
  1. Data are medians (IQR, 25th–75th quartiles) or proportions; aKruskal-Wallis one-way ANOVA with Dunn’s multiple comparison post-hoc test and χ2-test; ns, not significant; *p<0.05, **p≤0.01, *** p≤0.001; 2h-BG, 2h glycaemia after meals; ∆ BG, ∆ post-preprandial glycaemia; DR, Diabetic retinopathy; DN, Diabetic Neuropathy; eGFR was expressed as mL/min/1.73 m2.